以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡

doi:10.35541/cjd.20260100

中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (9): 844-849.doi: 10.35541/cjd.20260100

• 专家论坛·免疫介导炎症性皮肤病 • 上一篇下一篇

以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡

赵晴孙乐乐敖穗婷翟于凡刘红张福仁

山东第一医科大学附属皮肤病医院山东省皮肤病性病防治研究所，济南 250022

收稿日期:2026-02-26 修回日期:2026-07-28 发布日期:2026-09-03
通讯作者: 张福仁 E-mail:zhangfuren@hotmail.com
基金资助:
国家自然科学基金（82573985）

Analysis of immune dysregulation in drug hypersensitivity by using dapsone hypersensitivity syndrome as a model

Zhao Qing, Sun Lele, Ao Suiting, Zhai Yufan, Liu Hong, Zhang Furen

Dermatology Hospital of Shandong First Medical University, Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China

Received:2026-02-26 Revised:2026-07-28 Published:2026-09-03
Contact: Zhang Furen E-mail:zhangfuren@hotmail.com
Supported by:
National Natural Science Foundation of China（82573985）

摘要/Abstract

摘要： 【摘要】药物超敏反应是一种潜伏期长、临床表现复杂、可威胁生命的严重药物不良反应。本文以氨苯砜综合征为模型，深入剖析遗传、固有免疫及获得性免疫在药物超敏反应发生中的作用。基于此模型，提出当前药物超敏反应研究领域在预防、诊断、治疗中亟待解决的问题，并前瞻性地提出通过构建一个多因素风险预测模型，预防药物超敏反应的发生。

Abstract: 【Abstract】 Drug hypersensitivity is a severe adverse drug reaction characterized by a prolonged latency period, complex clinical manifestations, and a potentially life-threatening course. In this article, dapsone hypersensitivity syndrome serves as a model for dissecting the roles of genetic predisposition, innate immunity, and acquired immunity in the development of drug hypersensitivity. Based on this model, key unresolved challenges in the prevention, diagnosis, and treatment of drug hypersensitivity are proposed, and a multifactorial risk prediction model is expected to be established to guide the prevention of drug hypersensitivity.

Key words: Drug-related side effects and adverse reactions, Hypersensitivity, delayed, Dapsone, Dapsone hypersensitivity syndrome, Pharmacogenomic testing, Killer cells, natural, Tumor necrosis factor-alpha, Precision medicine

赵晴孙乐乐敖穗婷翟于凡刘红张福仁. 以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡[J]. 中华皮肤科杂志, 2026,59(9):844-849. doi:10.35541/cjd.20260100

Zhao Qing, Sun Lele, Ao Suiting, Zhai Yufan, Liu Hong, Zhang Furen. Analysis of immune dysregulation in drug hypersensitivity by using dapsone hypersensitivity syndrome as a model[J]. Chinese Journal of Dermatology, 2026, 59(9): 844-849.doi:10.35541/cjd.20260100

参考文献 47

［1］	Kroshinsky D, Cardones A, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms［J］. N Engl J Med, 2024,391（23）:2242⁃2254. DOI: 10.1056/NEJMra2204547.
［2］	Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions［J］. Nat Rev Dis Primers, 2024,10（1）:30. DOI: 10.1038/s41572⁃024⁃00514⁃0.
［3］	Komatsu⁃Fujii T, Kaneko S, Chinuki Y, et al. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions［J］. Allergol Int, 2017,66（1）:116⁃122. DOI: 10.1016/j.alit.2016.06.003.
［4］	Ogawa K, Morito H, Hasegawa A, et al. Identification of thymus and activation⁃regulated chemokine （TARC/CCL17） as a potential marker for early indication of disease and prediction of disease activity in drug⁃induced hypersensitivity syndrome （DIHS）/drug rash with eosinophilia and systemic symptoms （DRESS）［J］. J Dermatol Sci, 2013,69（1）:38⁃43. DOI: 10.1016/j.jdermsci.2012.10.002.
［5］	Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology［J］. Front Med （Lausanne）, 2017,4:179. DOI: 10.3389/fmed.2017.00179.
［6］	Dubin DP, Yassky D, Poplausky D, et al. Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series［J］. J Allergy Clin Immunol Pract, 2023,11（12）:3789⁃3791. DOI: 10.1016/j.jaip.2023.08.028.
［7］	Rubin L, Talmon A, Ribak Y, et al. Novel targeted inhibition of the IL⁃5 axis for drug reaction with eosinophilia and systemic symptoms syndrome［J］. Front Immunol, 2023,14:1134178. DOI: 10.3389/fimmu.2023.1134178.
［8］	Hama N, Abe R, Gibson A, et al. Drug⁃induced hypersensitivity syndrome （DIHS）/drug reaction with eosinophilia and systemic symptoms （DRESS）: clinical features and pathogenesis［J］. J Allergy Clin Immunol Pract, 2022,10（5）:1155⁃1167. DOI: 10.1016/j.jaip.2022.02.004.
［9］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. DOI: 10.1038/nm.1884.
［10］	Viard⁃Leveugle I, Gaide O, Jankovic D, et al. TNF⁃α and IFN⁃γ are potential inducers of Fas⁃mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis［J］. J Invest Dermatol, 2013,133（2）:489⁃498. DOI: 10.1038/jid.2012.330.
［11］	Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens⁃Johnson syndrome are induced by soluble Fas ligand［J］. Am J Pathol, 2003,162（5）:1515⁃1520. DOI: 10.1016/S0002⁃9440（10）64284⁃8.
［12］	Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug⁃specific cytotoxic T cells［J］. J Allergy Clin Immunol, 2004,114（5）:1209⁃1215. DOI: 10.1016/j.jaci.2004.07.047.
［13］	Cadot R, Gery P, Lenief V, et al. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology［J］. Allergy, 2025,80（1）:47⁃62. DOI: 10.1111/all.16316.
［14］	Umayahara T, Shimauchi T, Fujiyama T, et al. Paediatric acute generalized exanthematous pustulosis induced by paracetamol with high serum levels of interleukin⁃8 and ⁃22: a case report［J］. Acta Derm Venereol, 2013,93（3）:362⁃363. DOI: 10.2340/00015555⁃1462.
［15］	Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil⁃mediated inflammatory processes orchestrated by T cells［J］. Curr Opin Allergy Clin Immunol, 2002,2（4）:325⁃331. DOI: 10.1097/00130832⁃200208000⁃00006.
［16］	Marwa K, Goldin J, Kondamudi NP. TypeⅣ hypersensitivity reaction［M/OL］. Treasure Island （FL）: StatPearls Publishing, 2025［2026⁃02⁃26］. https://www.ncbi.nlm.nih.gov/books/NBK562228/.
［17］	Kardaun SH, Sekula P, Valeyrie⁃Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS）: an original multisystem adverse drug reaction. results from the prospective regiSCAR study［J］. Br J Dermatol, 2013,169（5）:1071⁃1080. DOI: 10.1111/bjd.12501.
［18］	Sun L, Huai P, Wang Z, et al. TSC22 domain family member 3 links natural killer cells to CD8+ T cell⁃mediated drug hypersensitivity［J］. Signal Transduct Target Ther, 2025,10（1）:196. DOI: 10.1038/s41392⁃025⁃02300⁃0.
［19］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. DOI: 10.1056/NEJMoa1213096.
［20］	Lowe J, Smith M. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones［J］. Int J Lepr, 1949,17（3）:181⁃195.
［21］	Allday EJ, Barnes J. Toxic effects of diaminodiphenylsulphone in treatment of leprosy［J］. Lancet, 1951,2（6675）:205⁃206. DOI: 10.1016/s0140⁃6736（51）91443⁃2.
［22］	Wozel G, Blasum C. Dapsone in dermatology and beyond［J］. Arch Dermatol Res, 2014,306（2）:103⁃124. DOI: 10.1007/s00403⁃013⁃1409⁃7.
［23］	Maddala RR, Ghorpade A, Adulkar S, et al. Anatopic response: double sparing phenomenon in a patient with dapsone hypersensitivity syndrome［J］. Indian J Dermatol Venereol Leprol, 2017,83（2）:241⁃243. DOI: 10.4103/0378⁃6323.193609.
［24］	Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review［J］. Acta Derm Venereol, 2012,92（2）:194⁃199. DOI: 10.2340/00015555⁃1268.
［25］	do Valle SO, França AT, Pires GV, et al. Dapsone hypersensitivity syndrome during delayed pressure urticaria treatment［J］. Ann Allergy Asthma Immunol, 2010,104（2）:181⁃182. DOI: 10.1016/j.anai.2009.11.041.
［26］	Zhu KJ, He FT, Jin N, et al. Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone⁃induced hypersensitivity syndrome［J］. J Clin Pharm Ther, 2009,34（4）:489⁃492. DOI: 10.1111/j.1365⁃2710.2008.00991.x.
［27］	Takahashi H, Tanaka M, Tanikawa A, et al. A case of drug⁃induced hypersensitivity syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus［J］. Clin Exp Dermatol, 2006,31（1）:33⁃35. DOI: 10.1111/j.1365⁃2230.2005.01913.x.
［28］	Grace M. An unusual case of dapsone syndrome［J］. Indian Dermatol Online J, 2011,2（2）:88⁃90. DOI: 10.4103/2229⁃5178.85999.
［29］	Hirahara K, Kano Y, Asano Y, et al. Osteonecrosis of the femoral head in a patient with henoch⁃schönlein purpura and drug⁃induced hypersensitivity syndrome treated with corticosteroids［J］. Acta Derm Venereol, 2013,93（1）:85⁃86. DOI: 10.2340/00015555⁃1417.
［30］	Thong BY, Leong KP, Chng HH. Hypersensitivity syndrome associated with dapsone/pyrimethamine （maloprim） antimalaria chemoprophylaxis［J］. Ann Allergy Asthma Immunol, 2002,88（5）:527⁃529. DOI: 10.1016/S1081⁃1206（10）62394⁃0.
［31］	Roth M, Gray JT, Peterson PG, et al. Dapsone⁃induced DRESS after infliximab⁃induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions［J］. BMJ Case Rep, 2020,13（12）:237560. DOI: 10.1136/bcr⁃2020⁃237560.
［32］	Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome⁃related lung injury without eosinophilia in the bronchoalveolar lavage fluid［J］. Intern Med, 2015,54（7）:827⁃831. DOI: 10.2169/internalmedicine.54.3406.
［33］	Chen WT, Wang CW, Lu CW, et al. The function of HLA⁃B*13:01 involved in the pathomechanism of dapsone⁃induced severe cutaneous adverse reactions［J］. J Invest Dermatol, 2018,138（7）:1546⁃1554. DOI: 10.1016/j.jid.2018.02.004.
［34］	Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone⁃ and nitroso dapsone⁃specific activation of T cells from hypersensitive patients expressing the risk allele HLA⁃B*13:01［J］. Allergy, 2019,74（8）:1533⁃1548. DOI: 10.1111/all.13769.
［35］	Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA⁃B*13:01 explains the risk of dapsone hypersensitivity syndrome［J］. J Dermatol Sci, 2017,88（3）:320⁃329. DOI: 10.1016/j.jdermsci.2017.08.007.
［36］	Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA⁃DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA⁃B*13:01［J］. J Invest Dermatol, 2018,138（5）:1101⁃1106. DOI: 10.1016/j.jid.2017.11.027.
［37］	Zhao Q, Almutairi M, Tailor A, et al. HLA class⁃2⁃restricted CD8+ T cells contribute to the promiscuous immune response in dapsone⁃hypersensitive patients［J］. J Invest Dermatol, 2021,141（10）:2412⁃2425.e2. DOI: 10.1016/j.jid.2021.03.014.
［38］	Jiang H, Wang CW, Wang Z, et al. Functional and structural characteristics of HLA⁃B*13:01⁃mediated specific T cells reaction in dapsone⁃induced drug hypersensitivity［J］. J Biomed Sci, 2022,29（1）:58. DOI: 10.1186/s12929⁃022⁃00845⁃8.
［39］	Sun L, Wang Z, Liu T, et al. TAP2 drives HLA⁃B∗13:01‒linked dapsone hypersensitivity syndrome tolerance and reactivity［J］. J Invest Dermatol, 2023,143（5）:722⁃730. DOI: 10.1016/j.jid. 2022.10.009.
［40］	Ao S, Gao X, Zhan J, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a cohort of patients［J］. J Am Acad Dermatol, 2022,86（6）:1236⁃1245. DOI: 10.1016/j.jaad.2022.01.039.
［41］	Chen X, Bäumel M, Männel DN, et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells［J］. J Immunol, 2007,179（1）:154⁃161. DOI: 10.4049/jimmunol.179.1.154.
［42］	Inoue M, Tsuji Y, Yoshimine C, et al. Structural optimization of a TNFR1⁃selective antagonistic tnfα mutant to create new⁃modality TNF⁃regulating biologics［J］. J Biol Chem, 2020,295（28）:9379⁃9391. DOI: 10.1074/jbc.RA120.012723.
［43］	Xue R, Li G, Zhou Y, et al. Efficacy and safety of low⁃dose interleukin 2 in the treatment of moderate⁃to⁃severe bullous pemphigoid: a single center perspective⁃controlled trial［J］. J Am Acad Dermatol, 2024,91（6）:1113⁃1117. DOI: 10.1016/j.jaad.2024.08.033.
［44］	Sun L, Zhao Q, Ao S, et al. Feedback regulation of VISTA and Treg by TNF⁃α controls T cell responses in drug allergy［J］. Allergy, 2025,80（5）:1400⁃1416. DOI: 10.1111/all.16393.
［45］	Campbell CN, Krantz MS, Yu A, et al. HLA⁃B*58:01 and risk of allopurinol⁃induced severe cutaneous adverse reactions in the US［J］. JAMA Dermatol, 2025,161（12）:1258⁃1263. DOI: 10.1001/jamadermatol.2025.4240.
［46］	Pan RY, Chu MT, Wang CW, et al. Identification of drug⁃specific public TCR driving severe cutaneous adverse reactions［J］. Nat Commun, 2019,10（1）:3569. DOI: 10.1038/s41467⁃019⁃11396⁃2.
［47］	Aggarwal R, Sharma M, Modi M, et al. HLA⁃B∗ 1502 is associated with carbamazepine induced Stevens⁃Johnson syndrome in north Indian population［J］. Hum Immunol, 2014,75（11）:1120⁃1122. DOI: 10.1016/j.humimm.2014.09.022.

[1]	中华医学会皮肤性病学分会中华医学会变态反应学分会中国麻风防治协会. [开放获取] 中国药疹诊疗指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(9): 811-826.
[2]	李燕红姜琨吴卓璇章建兰方美珍刘姝婷王琳琳胡磊周小勇陈柳青陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787.
[3]	张笑旭罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2026, 59(5): 459-463.
[4]	中国医学装备协会皮肤病与皮肤美容分会中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(4): 304-319.
[5]	许国康蔡梅. 索立德吉治疗局部晚期基底细胞癌8例临床分析[J]. 中华皮肤科杂志, 2026, 59(2): 166-169.
[6]	张峰源陈思涵周子桢周蒙曾荣陈旭练霓李岷. 痤疮丙酸杆菌通过诱导角质形成细胞发生Gasdermin E介导的焦亡促进痤疮炎症反应[J]. 中华皮肤科杂志, 2025, 58(7): 623-629.
[7]	邱里肖汀. 布鲁顿酪氨酸激酶抑制剂在慢性自发性荨麻疹治疗中的进展[J]. 中华皮肤科杂志, 2025, 58(6): 563-567.
[8]	吕铭悦满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377.
[9]	叶瑞贤薛如君梁景耀张锡宝. circ_0086376靶向miR-5195-3p对痤疮丙酸杆菌介导的HaCaT细胞炎症因子表达的调控作用研究[J]. 中华皮肤科杂志, 2025, 58(4): 340-346.
[10]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.
[11]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[12]	焦磊梁源汪洋申春平向欣徐哲肖媛媛李丽刘盈张斌徐子刚马琳. 儿童药物超敏反应综合征103例临床特征回顾性分析[J]. 中华皮肤科杂志, 2025, 58(10): 936-942.
[13]	皮江珊陈静思王凌凌沈沾婷罗晓燕王华. 度普利尤单抗治疗6个月至2岁中重度特应性皮炎患儿的前瞻性、单中心临床研究[J]. 中华皮肤科杂志, 2025, 58(10): 930-935.
[14]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[15]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.

以氨苯砜综合征为模型解析药物超敏反应中的免疫失衡

Analysis of immune dysregulation in drug hypersensitivity by using dapsone hypersensitivity syndrome as a model

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

Metrics

本文评价

推荐阅读 10